Tipifarnib in Treating Patients With Recurrent Bladder Cancer

Completed · Phase 2

Conditions studied: Bladder Cancer

In brief

RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of tipifarnib in treating patients who have recurrent bladder cancer.

Key facts

Study ID

NCT00047216

Run by

University Health Network, Toronto

Starts

2002-11-01

Last updated by the study team

2015-07-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Chicago Cancer Research Center — Chicago, Illinois, United States
• Louis A. Weiss Memorial Hospital — Chicago, Illinois, United States
• Vancouver General Hospital — Vancouver, British Columbia, Canada
• St. Joseph's Hospital — Hamilton, Ontario, Canada
• London Regional Cancer Program at London Health Sciences Centre — London, Ontario, Canada
• Sunnybrook and Women's College Health Sciences Centre — North York, Ontario, Canada
• Princess Margaret Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.